Trending Topic

Breast Cancer
29 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (SERMs; tamoxifen), aromatase inhibitors (AIs; anastrazole, letrozole and exemestane) and selective oestrogen receptor degraders (SERDs; fulvestrant […]

Lynsey Drewett, AACR 2022: Olaparib in Combination With Neoadjuvant Platinum-based Chemotherapy – the PARTNER Study

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: May 10th 2022

It was a pleasure to speak with Dr Lynsey Drewett (University of Cambridge, Cambridge, UK) around the PARTNER study, investigating the efficacy and safety of the addition of olaparib to neoadjuvant platinum-based chemotherapy in the treatment of basal TNBC and/or gBRCA breast cancer.

The abstract ‘PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of Olaparib to Platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.’ (Abstract number CT562) was presented at AACR 2022, 8-13 April, 2022

Questions

  1. What are the unmet needs in the treatment of triple negative breast cancer (TNBC) and germline BRCA (gBRCA) breast cancer? (0:18)
  2. What was the rationale for the addition of olaparib to neoadjuvant platinum-based chemotherapy in the treatment of basal TNBC and/or gBRCA breast cancer? (1:26)
  3. What are the aims, design and eligibility criteria for the PARTNER study? (2:49)
  4. What are the endpoints for stage 1, 2 and 3 of the study and how well have these been achieved so far? (3:54)
  5. Please could you give a brief overview of the Partnering substudy? (4:55)

Disclosures: Lynsey Drewett has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of the AACR annual meeting 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup